The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
